New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:13 EDTMGNXMacroGenics price target raised to $51 from $35 at Stifel
Stifel increased its price target on MacroGenics as the firm thinks the company is uniquely positioned to benefit from investor enthusiasm for targeted combination therapy in the immuno-oncology space. The firm believes the company has best-in-class technology, while recent data has increased Stifel's confidence in the company's approach. It keeps a Buy rating on the shares.
News For MGNX From The Last 14 Days
Check below for free stories on MGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 5, 2014
11:00 EDTMGNXMacroGenics management to meet with Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use